Current Projects
Principle Investigators
During 2007, Helen Hayes Hospital scientists in the Clinical Research Center (CRC) maintained their position of internationally recognized excellence in clinical research of metabolic bone disease. Results from their research studies appeared in various leading journals, such as the New England Journal of Medicine, Annals of Internal Medicine, Nutrition and Metabolism (London), Journal of Bone and Mineral Research and American Journal of Clinical Nutrition.
Nieves JW, Li T, Zion M, Gussekloo J, Pahor M, Bernabei R, Simon H, Williams GR, Lapuerta P. The clinically meaningful change in physical performance scores in an elderly cohort. Aging Clin Exp Res. 2007 Dec;19(6):484-91.
Nieves JW, Lindsay R. Calcium and fracture risk. Am J Clin Nutr. 2007 Dec;86(6):1579-80.
Nieves JW, Barrett-Connor E, Siris ES, Zion M, Barlas S, Chen YT. Calcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) study. Osteoporos Int. 2007 Nov 13; [Epub ahead of print]
Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int. 2007 Oct 11; [Epub ahead of print]
Cobb KL, Bachrach LK, Sowers M, Nieves J, Greendale GA, Kent KK, Brown BW Jr, Pettit K, Harper DM, Kelsey JL. The effect of oral contraceptives on bone mass and stress fractures in female runners. Med Sci Sports Exerc. 2007 Sep;39(9):1464-73.
Kelsey JL, Bachrach LK, Procter-Gray E, Nieves J, Greendale GA, Sowers M, Brown BW Jr, Matheson KA, Crawford SL, Cobb KL. Risk factors for stress fracture among young female cross-country runners. Med Sci Sports Exerc. 2007 Sep;39(9):1457-63.
Ruffing JA, Nieves JW, Zion M, Tendy S, Garrett P, Lindsay R, Cosman F. The influence of lifestyle, menstrual function and oral contraceptive use on bone mass and size in female military cadets. Nutr Metab (Lond). 2007 Aug 6;4:17.
Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res. 2007 Apr;22(4):495-502.
Iida-Klein A, Lu SS, Cosman F, Lindsay R, Dempster DW. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone. 2007 Feb;40(2):391-8.
Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int. 2007 Jan;18(1):25-34.
Shane E, Civitelli R, Delmas PD, Drezner M, Eisman JA, Lindsay R, Lorenzo J, Miller P, Ralston S, Reid I, Siris E. Maintaining the trust of physicians and the public in the medical literature: report of a task force on scientific publishing of clinical trials.J Bone Miner Res. 2007 Nov;22(11):1661-7.
Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab. 2007 Dec;92(12):4671-7. Epub 2007 Aug 28.
Thorneycroft IH, Lindsay R, Pickar JH. Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial. Am J Obstet Gynecol. 2007 Aug;197(2):137.e1-7.
Johnston S, Andrews S, Shen V, Cosman F, Lindsay R, Dempster DW, Iida-Klein A. The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice. Endocrinology. 2007 Sep;148(9):4466-74. Epub 2007 Jun 14.
Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007 May;40(5):1238-43. Epub 2007 Feb 8.
Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB; Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007 Mar 6;146(5):326-39.
Cosman F, Borges JL, Curiel MD. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. Clin Ther. 2007 Jun;29(6):1116-27. Review.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3;356(18):1809-22.
Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin. 2007 Mar;23(3):585-94. |
